Julia A. Bridge, MD, FACMG

Professor (Clinical), University of Utah School of Medicine

Specialties

• Bone and soft tissue pathology
• Cytopathology
• Cytogenetics and molecular oncology (solid tumors)

Education

• Medical Degree—University of Nebraska Medical Center
• Residency—Pathology, University of Kansas Medical Center
• Fellowship—Molecular Genetics, Southwest Biomedical Research Institute
• Fellowship—Cytogenetics, University of Kansas Medical Center
• Fellowship—Cytogenetics, University of Nebraska Medical Center

Certification/Affiliations

• American Board of Medical Genetics (Clinical Cytogenetics)
• American Board of Pathology (Anatomic Pathology)

Research Interests

• Bone and soft tissue tumors
• Molecular and cytogenomic profiling of solid tumors

Awards

• Maude Abbott Lecture Award, United States and Canadian Academy of Pathology (USCAP)
• President, United States and Canadian Academy of Pathology (USCAP)
• Amelia F. and Austin L. Vickery Jr., Chair in Pathology, University of Nebraska Foundation
• K. Mostofi Distinguished Service Award, USCAP
• CTOS Herman Suit Special Award Lecture, Connective Tissue Oncology Society
• President, International Society of Bone and Soft Tissue Pathology
• Secretarial Appointee, Department of Veterans Affairs, Genomic Medicine Program Advisory Committee
• Fred Waldorf Stewart Award, Memorial Sloan Kettering Cancer Center
• Young Investigator Award, USCAP
• Kappa Delta Young Investigator Award, American Academy of Orthopaedic Surgeons
• Kappa Delta Ann Doner Vaughn Award, American Academy of Orthopaedic Surgeons

Recent Publications  

• O'Connor P, Bridge JA, Meis JM, et al. Myxoid "pauci-hemosiderotic" fibrolipomatous tumour: a diagnostic challenge. Histopathology. 2025;86(4):647-649.
• Papke DJ Jr, Chrisinger JSA, French CA, et al. MAD::NUT-fusion sarcoma: a sarcoma class with NUTM1, NUTM2A and NUTM2G fusions and possibly distinctive subtypes. Mod Pathol. 2025:100729
• Acosta AM, Fletcher CDM, Sholl LM, et al. Fluorescence in-situ hybridization assessment of spindle cell-rich testicular sex cord stromal tumors demonstrates multiple chromosomal gains across histologic subtypes. Hum Pathol. 2024;153:105652
• Sta Ines FMG, Marketkar S, Ng S, et al. Myoid hamartoma of the breast with HMGA2 rearrangement and associated in-situ and invasive carcinoma: case report and review of literature. Int J Surg Pathol. 2024:10668969241271420.
• Collins K, Bridge JA, Mehra R, et al. Renal epithelioid angiomyolipomas overexpress TFE3 and the TFE3-regulated gene TRIM63 in the absence of TFE3 rearrangement. Virchows Arch. 2024;485(3):471-478
• Amin SE, Lewis JS Jr, Bridge JA, et al. DEK::AFF2 fusion-associated squamous cell carcinoma: a case series with literature review on an emerging and challenging entity. Head Neck Pathol. 2024;18(1):86.
• Whaley RD, Agaimy A, Bridge JA, et al. Xanthogranulomatous epithelial tumors/keratin-positive giant cell-rich tumors involving the head and neck: report of seven cases and review of the literature. Virchows Arch. 2024;485(4):605-613.
• Machado I, Agaimy A, Giner F, et al. The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms. Virchows Arch. 2024;484(5):765-775.
• Bridge JA, Halling KC, Moncur JT, et al. RNA sequencing for solid tumor fusion gene detection: proficiency testing practice and performance comparison. Arch Pathol Lab Med. 2024;148(5):538-544.
• Surucu A, de Biase D, Ricci C, et al. Beta-catenin alterations in post-chemotherapy yolk sac tumor, postpubertal-type with enteroblastic features. Mod Pathol. 2024;37(7):100513.
• Mezzacappa FM, Smith FK, Zhang W, et al. Potential prognostic determinants for FET::CREB fusion-positive intracranial mesenchymal tumor. Acta Neuropathol Commun. 2024;12(1):17.
• Machado I, Llombart-Bosch A, Charville GW, et al. Sarcomas with EWSR1::non-ETS fusion (EWSR1::NFATC2 and EWSR1::PATZ1). Surg Pathol Clin. 2024;17(1):31-55.
• Hagemann IS, Bridge JA, Tafe LJ, et al. Current laboratory testing practices for assessment of ERBB2/HER2 in endometrial serous carcinoma and colorectal carcinoma. Arch Pathol Lab Med. 2023;147(10):1148-1157.
• Crowley HM, Georgantzoglou N, Tse JY, et al. Expanding our knowledge of molecular pathogenesis in histiocytoses: solitary soft tissue histiocytomas in children with a novel CLTC::SYK fusion. Am J Surg Pathol. 2023;47(10):1108-1115.
• Gangahar CN, Dehner CA, Wang DP, et al. Intraosseous hibernoma: clinicopathologic and imaging analysis of 18 cases. Histopathology. 2023;83(1):40-48.
• Machado I, Hosler GA, Traves V, et al. Superficial GLI1-amplified mesenchymal neoplasms: expanding the spectrum of an emerging entity which reaches the realm of dermatopathology. J Cutan Pathol. 2023;50(6):487-499.
• Zota V, Siegal GP, Kelly D, et al. Validation of PRKCB immunohistochemistry as a biomarker for the diagnosis of Ewing sarcoma. Fetal Pediatr Pathol. 2023;42(2):241-252.
• Acosta AM, Bridge JA, Dal Cin PS, et al. Inflammatory and nested testicular sex cord tumor: a novel neoplasm with aggressive clinical behavior and frequent EWSR1::ATF1 gene fusions. Am J Surg Pathol. 2023;47(4):504-517.
• Bove JVMG, Webster F, Amary F, et al. Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2023;82(4):531-540.
• Palsgrove DN, Rooper LM, Stevens TM, et al. GLI1-altered soft tissue tumors of the head and neck: frequent oropharyngeal involvement, p16 immunoreactivity, and detectable alterations by DDIT3 break apart FISH. Head Neck Pathol. 2022;16(4):1146-1156.
• Georgantzoglou N, Green D, Winnick KN, et al. Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation. Genes Chromosomes Cancer. 2022;61(8):471-480.
• Brat DJ, Aldape K, Bridge JA, et al. Molecular biomarker testing for the diagnosis of diffuse gliomas. Arch Pathol Lab Med. 2022;146(5):547-574.
• Ramkissoon SH, Fernandes H, Lopez-Terrada DH, et al. Clinical laboratory testing practices in diffuse gliomas prior to publication of 2021 World Health Organization Classification of Central Nervous System Tumors. Arch Pathol Lab Med. 2022;147(5):518-524.
• Strait AM, Bridge JA, Iafrate AJ, et al. Mammary-type myofibroblastoma with leiomyomatous differentiation: a rare variant with potential pitfalls. Int J Surg Pathol. 2022;30(2):200-206.
• Patton A, Bridge JA, Liebner D, et al. A YAP1::TFE3 cutaneous low-grade fibromyxoid neoplasm: a novel entity! Genes Chromosomes Cancer. 2022;61(4):194-199.
• Campbell K, Bridge JA, DiMaio D, et al. Dermatofibrosarcoma protuberans with platelet-derived growth factor-D rearrangement; two cases with morphologically distinct presentations. J Cutan Pathol. 2022;49(3):274-277.
• Lindsey MS, Bridge JA, Douglas DS, et al. Primary cutaneous alveolar rhabdomyosarcoma in an elderly adult: a rare potential mimic of Merkel cell carcinoma. Am J Dermatopathol. 2022;44(3):218-222.
• Cowan B, Klein E, Jansz K, et al. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer. BJU Int. 2021;128(6):713-721.
• Kerr DA, Thompson LDR, Tafe LJ, et al. Clinicopathologic and genomic characterization of inflammatory myofibroblastic tumors of the head and neck: highlighting a novel fusion and potential diagnostic pitfall. Am J Surg Pathol. 2021;45(12):1707-1719.
• Sadaf A, Szabo S, Ferguson K, et al. Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib. Cancer. 2021;127(22):4124-4130.
• Hughes CE, Correa H, Benedetti DJ, et al. Second report of PDE10A-BRAF fusion in pediatric spindle cell sarcoma with infantile fibrosarcoma-like morphology suggesting PDE10A-BRAF fusion is a recurrent event. Pediatr Dev Pathol. 2021;24(6):554-558.
• Al-Obaidy KI, Bridge JA, Cheng L, et al. EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Mod Pathol. 2021;34(10):1921-1934.
• Parra O, Bridge JA, Busam KJ, et al. Dermal melanocytic tumor with CRTC1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity. J Cutan Pathol. 2021;48(7):915-924.
• Wang H, Weiss VL, Hoffman RD, et al. Salivary gland NUT carcinoma with prolonged survival in children: case illustration and systematic review of literature. Head Neck Pathol. 2021;15(1):236-243.
• Motanagh S, Bridge JA, Linos K. Acral fibromyxoma with loss of Rb1 by immunohistochemistry and fluorescence in situ hybridization: A diagnostically exploitable marker. J Cutan Pathol. 2021;48(2):295-301.
• Valenberg FJPV, Hiar AM, Wallace E, et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Oncol. 2021;4(1):93-101.
• Pettus JR, Kerr DA, Stan RV, et al. Primary myxoid and epithelioid mesenchymal tumor of the kidney with a novel GLI1-FOXO4 fusion. Genes Chromosomes Cancer. 2021;60(2):116-122.
• Linos K, Kerr DA, Sumegi J, et al. Pan-Trk immunoexpression in a superficial malignant ossifying fibromyxoid tumor with ZC3H7B-BCOR fusion: a potential obfuscating factor in the era of targeted therapy. J Cutan Pathol. 2021;48(2):340-342.
• Bridge JA, Sumegi J, Royce T, et al. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone. Genes Chromosomes Cancer. 2021;60(1):38-42.
• Parra O, Kerr DA, Bridge JA, et al. A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility. J Cutan Pathol. 2021;48(1):95-101.